Compare NMRA & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMRA | HRZN |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.3M | 322.2M |
| IPO Year | 2023 | N/A |
| Metric | NMRA | HRZN |
|---|---|---|
| Price | $1.63 | $4.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $7.50 | $6.50 |
| AVG Volume (30 Days) | ★ 685.8K | 572.5K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 33.85% |
| EPS Growth | ★ 5.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.25 |
| Revenue Next Year | N/A | $22.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $3.80 |
| 52 Week High | $3.65 | $7.28 |
| Indicator | NMRA | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 55.00 |
| Support Level | $1.50 | $4.56 |
| Resistance Level | $1.72 | $4.76 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 72.00 | 79.61 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.